Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
08
09
2022
accepted:
20
03
2023
revised:
22
02
2023
medline:
10
7
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Splenomegaly is a hallmark of myelofibrosis (MF), and reports on the impact of spleen size on the outcome of allo-HSCT have been conflicting, possibly due to differences in methods of assessment. We retrospectively analysed the impact of spleen volume and length measured by computed tomography on allo-HSCT outcome in 93 patients, 74% of whom had prior ruxolitinib treatment. Median spleen volume and length were 1.58 dm
Identifiants
pubmed: 37002409
doi: 10.1038/s41409-023-01968-8
pii: 10.1038/s41409-023-01968-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-761Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–65. https://doi.org/10.1056/NEJM200004273421706 .
doi: 10.1056/NEJM200004273421706
pubmed: 10781623
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–45. https://doi.org/10.3324/haematol.2014.119545 .
doi: 10.3324/haematol.2014.119545
pubmed: 26069290
pmcid: 4800694
Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114:5264–70. https://doi.org/10.1182/blood-2009-07-234880 .
doi: 10.1182/blood-2009-07-234880
pubmed: 19812383
Tiribelli M, Palandri F, Sant’Antonio E, Breccia M, Bonifacio M. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. Bone Marrow Transplant. 2020;55:708–16. https://doi.org/10.1038/s41409-019-0683-1 .
doi: 10.1038/s41409-019-0683-1
pubmed: 31534197
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–42. https://doi.org/10.1182/blood-2018-12-890889 .
doi: 10.1182/blood-2018-12-890889
pubmed: 30760453
Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125:3347–50. https://doi.org/10.1182/blood-2014-10-608315 .
doi: 10.1182/blood-2014-10-608315
pubmed: 25784679
pmcid: 4440886
Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120:1367–79. https://doi.org/10.1182/blood-2012-05-399048 .
doi: 10.1182/blood-2012-05-399048
pubmed: 22700718
pmcid: 5800543
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, et al. Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment. Clin Lymphoma Myeloma Leuk. 2016;16:297–303. https://doi.org/10.1016/j.clml.2016.02.004 .
doi: 10.1016/j.clml.2016.02.004
pubmed: 27025789
Polverelli N, Mauff K, Kroger N, Robin M, Beelen D, Beauvais D. et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European Society for Blood and Marrow Transplantation (EBMT). Am J Hematol. 2021;96:69–79. https://doi.org/10.1002/ajh.26020 .
doi: 10.1002/ajh.26020
pubmed: 33064301
Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45:458–63. https://doi.org/10.1038/bmt.2009.188 .
doi: 10.1038/bmt.2009.188
pubmed: 19718055
Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuk F, Triviai I, et al. Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis. J Nucl Med. 2016;57:1556–9. https://doi.org/10.2967/jnumed.115.166348 .
doi: 10.2967/jnumed.115.166348
pubmed: 27230931
Bezerra AS, D’Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement. AJR Am J Roentgenol. 2005;184:1510–3. https://doi.org/10.2214/ajr.184.5.01841510 .
doi: 10.2214/ajr.184.5.01841510
pubmed: 15855107
Kucybala I, Ciuk S, Teczar J. Spleen enlargement assessment using computed tomography: which coefficient correlates the strongest with the real volume of the spleen. Abdom Radio (NY). 2018;43:2455–61. https://doi.org/10.1007/s00261-018-1500-9 .
doi: 10.1007/s00261-018-1500-9
Yetter EM, Acosta KB, Olson MC, Blundell K. Estimating splenic volume: sonographic measurements correlated with helical CT determination. AJR Am J Roentgenol. 2003;181:1615–20. https://doi.org/10.2214/ajr.181.6.1811615 .
doi: 10.2214/ajr.181.6.1811615
pubmed: 14627584
Mazonakis M, Damilakis J, Maris T, Prassopoulos P, Gourtsoyiannis N. Estimation of spleen volume using MR imaging and a random marking technique. Eur Radio. 2000;10:1899–903. https://doi.org/10.1007/s003300000551 .
doi: 10.1007/s003300000551
Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152:331–9. https://doi.org/10.1111/j.1365-2141.2010.08417.x .
doi: 10.1111/j.1365-2141.2010.08417.x
pubmed: 21133885
Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, et al. The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:958–64. https://doi.org/10.1016/j.bbmt.2017.03.002 .
doi: 10.1016/j.bbmt.2017.03.002
pubmed: 28263921
Helbig G, Wieczorkiewicz-Kabut A, Markiewicz M, Krzemien H, Wojciak M, Bialas K, et al. Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. Med Oncol. 2019;36:16. https://doi.org/10.1007/s12032-019-1245-5 .
doi: 10.1007/s12032-019-1245-5
pubmed: 30617767
pmcid: 6326000
Stubig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28:1736–8. https://doi.org/10.1038/leu.2014.86 .
doi: 10.1038/leu.2014.86
pubmed: 24569777
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant. 2016;22:432–40. https://doi.org/10.1016/j.bbmt.2015.10.005 .
doi: 10.1016/j.bbmt.2015.10.005
pubmed: 26493563
Robin M, Francois S, Huynh A, Cassinat B, Bay J-O, Cornillon J, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored By Goelams-FIM in collaboration with the SFGMTC. Blood. 2013;122:306. https://doi.org/10.1182/blood.V122.21.306.306 .
doi: 10.1182/blood.V122.21.306.306
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8. https://doi.org/10.1182/blood-2013-03-488098 .
doi: 10.1182/blood-2013-03-488098
pubmed: 23838352
pmcid: 4828070
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20:382–6. https://doi.org/10.1016/j.bbmt.2013.11.034 .
doi: 10.1016/j.bbmt.2013.11.034
pubmed: 24321747
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. https://doi.org/10.2307/2670170 .
doi: 10.2307/2670170.
Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856–64. https://doi.org/10.1038/s41375-021-01449-1 .
doi: 10.1038/s41375-021-01449-1
pubmed: 34663912
Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018;101:305–17. https://doi.org/10.1111/ejh.13099 .
doi: 10.1111/ejh.13099
pubmed: 29791053
Kroger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551–60. https://doi.org/10.1038/s41375-021-01276-4 .
doi: 10.1038/s41375-021-01276-4
pubmed: 34023851
pmcid: 8632691